Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To register, simply click the Register button at the top right.
i thought my tests was just of the number and not function.. but on looking again at this thread, i saw dr yes's post and hence now are confused
That lab result is an NK cell count, like the 'census' measurements Hope and I mentioned earlier in this thread. It was normal in your case, as it is in many ME/CFS patients. It does not, however, tell you about function. For that you would need a different kind of test (the NK functional assay described earlier).and wondering if they are lf NK cell function results after all. I read all the posts here again and are even more confused.
i had a Immunophenotyping test/ Lymphoctye surface markers - flow cytometry
It says Natural killer Cell Markers CD3-/CD (16+56)+ result was 10% (normal 2-24) .. Is this percentage indicative of the function?
So my big question is .. is my NK cells normal?? (i actually find that strange if so as i ad this blood test done back several years ago when i was mostly housebound.. Unfortunately i have got no tests thou from back when i was extremely sick).
That lab result is an NK cell count, like the 'census' measurements Hope and I mentioned earlier in this thread. It was normal in your case, as it is in many ME/CFS patients. It does not, however, tell you about function. For that you would need a different kind of test (the NK functional assay described earlier).
Anika is right regarding both the lab Klimas uses (her own lab through University of Miami) and the time sensitivity required in performing NK function testing.
The reason to test for NK function is that it is almost universal in CFS patients as a diagnostic biomarker. There are very few diseases (HIV being another) where NK activity is as low as it is within the CFS population. I can tell you that Klimas absolutely uses NK function as a biomarker in diagnosis and is continually remeasuring the activity (along with cytokine levels and other immune components) to assess recovery. For those of you looking to increase NK function.... I've been on immunovir and am currently taking Immpower (medicinal mushrooms). They both have significant studies supporting their immune modulation effects and raise NK function.
Yes, that is exactly right. I have been to Miami twice in the last two months. Dr. Klimas did a ton of immune testing. My natural killer cells were operating at only 25% and I had 5 times the inflammatory cytokins than I should. She has started me on Imunovir..so far so good. She mentioned Oxymartine for a later date. She believes in going slowly we are all so senstive. I am planning to post about the experience but have been very tired but I will. I started a couple times but gave up.
NKC Cytotoxicity Assay
In this assay the cytotoxic activity of nk cells in blood was measured by the release of 51 Cr from NK cell sensitive tumor cells targets K562 following a 4 hr incubation of target cells with effector cells. The number of NK cells in the blood was determined using the flow cytometer to measure the % of lymphocytes that were CD56+ and CD3-
nk cell enumerations (CD56+CD3-lymphocytes):
1.9% range is 3-13%
48 range is 63-291
nk cell activity (% target cells killed at a 1:1 ratio of target cells to effector cells):
4.3% range is 5-21%
Comments: This assay was done from 8 to 24hrs from the time of the draw.
Additional test: Just the measure of the nk cell absolute #.
39 range is 98-294
In summary, my NK values are low, low, low.
Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome.
Natural killer (NK) cell activity was measured blindly in vitro with blood specimens from 50 healthy individuals and 20 patients with clinically defined chronic fatigue immune dysfunction syndrome (CFIDS) who met the criteria established by the Centers for Disease Control and Prevention (Atlanta). In accordance with a group scoring system of 1-10 points, with 10 being the most severe clinical status, the patient population was stratified into three clinical groups: A (> 7 points), B (5-7 points), and C (< 5 points). NK cell activity was assessed by the number of lytic units (LU), which for the 50 healthy controls varied between 20 and 250 (50%, 20-50 LU; 32%, 51-100 LU; 6%, 101-130 LU; and 12%, > 150 LU). In none of the 20 patients with CFIDS was the NK cell activity > 100 LU. For group C, the 10 patients stratified as having the least severe clinical condition, the measure was 61.0 +/- 21.7 LU; for group B (more severe, n = 7), it was 18.3 +/- 7.3 LU; and for group A (most severe, n = 3), it was 8.0 +/- 5.3 LU. These data suggest a correlation between low levels of NK cell activity and severity of CFIDS, which, if it is confirmed by additional studies of larger groups, might be useful for subgrouping patients and monitoring therapy and/or the progression of CFIDS.
This was in the context of 1994, and look how little has been done.